RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting m6A methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype. This evidence concerns the gene TNFSF9 and triple-negative breast carcinoma.